{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:18Z","timestamp":1790612118637,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,8]]},"DOI":"10.7759\/cureus.27778","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T14:13:47Z","timestamp":1659968027000},"source":"Crossref","is-referenced-by-count":1,"title":["Recurrent Chylous Pleural Effusions in a Patient Treated With Dasatinib"],"prefix":"10.7759","author":[{"given":"Syed Alishan","family":"Nasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Calavia Liano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2004.05.006","article-title":"Tyrosine kinase inhibitors in cancer therapy","volume":"37","author":"Madhusudan S","year":"2004","unstructured":"Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem. 2004, 37:618-35. 10.1016\/j.clinbiochem.2004.05.006","journal-title":"Clin Biochem"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/11207580-000000000-00000","article-title":"Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"71","author":"McCormack PL","year":"2011","unstructured":"McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011, 71:1771-95. 10.2165\/11207580-000000000-00000","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S80207","article-title":"The role of dasatinib in the management of chronic myeloid leukemia","volume":"9","author":"Chen R","year":"2015","unstructured":"Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther. 2015, 9:773-9. 10.2147\/DDDT.S80207","journal-title":"Drug Des Devel Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2012.0196","article-title":"Dasatinib-related chylothorax","volume":"32","author":"Huang YM","year":"2015","unstructured":"Huang YM, Wang CH, Huang JS, et al.. Dasatinib-related chylothorax. Turk J Haematol. 2015, 32:68-72. 10.4274\/tjh.2012.0196","journal-title":"Turk J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian HM","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, et al.. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012, 119:1123-9. 10.1182\/blood-2011-08-376087","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00932-3","article-title":"Dasatinib-induced chylothorax: report of a case and review of the literature","volume":"38","author":"Chen B","year":"2020","unstructured":"Chen B, Wu Z, Wang Q, Li W, Cheng D. Dasatinib-induced chylothorax: report of a case and review of the literature. Invest New Drugs. 2020, 38:1627-32. 10.1007\/s10637-020-00932-3","journal-title":"Invest New Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231653","article-title":"Chylothorax: complication attributed to dasatinib use","volume":"12","author":"Al-Abcha A","year":"2019","unstructured":"Al-Abcha A, Iftikhar MH, Abu Rous F, Laird-Fick H. Chylothorax: complication attributed to dasatinib use. BMJ Case Rep. 2019, 12:e231653. 10.1136\/bcr-2019-231653","journal-title":"BMJ Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2017.11929535","article-title":"Dasatinib-induced chylothorax in chronic myeloid leukemia","volume":"30","author":"Baloch ZQ","year":"2017","unstructured":"Baloch ZQ, Abbas SA, Bhatti H, Braver Y, Ali SK. Dasatinib-induced chylothorax in chronic myeloid leukemia. Proc (Bayl Univ Med Cent). 2017, 30:71-73. 10.1080\/08998280.2017.11929535","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3002-19","article-title":"Successful control of dasatinib-related chylothorax by the Japanese herbal medicine \"Goreisan\"","volume":"58","author":"Sasaki H","year":"2019","unstructured":"Sasaki H, Kimizuka Y, Ogata H, et al.. Successful control of dasatinib-related chylothorax by the Japanese herbal medicine \"Goreisan\". J-STAGE. 2019, 58:3139-41. 10.2169\/internalmedicine.3002-19","journal-title":"J-STAGE"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/108478-recurrent-chylous-pleural-effusions-in-a-patient-treated-with-dasatinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:43Z","timestamp":1707507463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/108478-recurrent-chylous-pleural-effusions-in-a-patient-treated-with-dasatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.27778","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,8]]}}}